32 recruiting. 32 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Recruiting 32 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | Pfizer | 1100 | 2026-09-30 | 2026-10-09 |
| A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) HFA-152a, HFA-134a - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 110 | 2026-09-01 | 2026-09-30 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2) GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 370 | 2026-08-27 | 2026-09-30 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1) GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 514 | 2026-08-27 | 2026-09-25 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | Pfizer | 1100 | 2026-08-20 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149 - Asthma | Phase 3 | Recruiting | Novartis Pharmaceuticals | 188 | 2026-08-04 | 2026-10-15 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-10-27 |
| Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists Experimental: Participant Group CHF 5993 pMDI HFA-152a, Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a - Asthma | Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 554 | 2026-06-26 | 2026-07-08 |
| A Study of Depemokimab in Participants of 6 to 11 Years of Age Depemokimab - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 34 | 2026-06-25 | 2026-08-26 |
| Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER® - Asthma (Diagnosis) | Phase 3 | Recruiting | Lunan Better Pharmaceutical Co., LTD. | 416 | 2026-06-08 | 2026-08-17 |
| A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma Depemokimab, Placebo - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 456 | 2026-03-13 | 2026-08-17 |
| A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma Dupilumab Prefilled Syringe, Placebo Injection - Asthma Control | Phase 3 | Recruiting | Université de Sherbrooke | 150 | 2026-01-29 | 2026-10-02 |
| Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab Tezepelumab - Severe Asthma | Phase 3 | Recruiting | AstraZeneca | 400 | 2026-01-28 | 2026-11-04 |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) GB-0895, Placebo - Severe Asthma | Phase 3 | Recruiting | Generate Biomedicines | 786 | 2026-01-20 | 2026-11-03 |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) GB-0895, Placebo - Severe Asthma | Phase 3 | Recruiting | Generate Biomedicines | 786 | 2025-12-03 | 2026-10-22 |
| Magnesium Trial in Acute Asthma in Emergency Department magnesium sulfate, Normal Saline - Asthma | Phase 3 | Recruiting | Suzanne Schuh | 192 | 2025-10-08 | 2025-12-18 |
| A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma SHR-1905 Injection, SHR-1905 Placebo Injection - Asthma | Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 408 | 2025-09-03 | 2025-09-09 |
| Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma MG-K10/Placebo - Asthma | Phase 3 | Recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 504 | 2025-03-25 | 2025-04-17 |
| TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection TQC2731 injection, Placebo - Asthma | Phase 3 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 660 | 2025-03-21 | 2026-08-19 |
| VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma Cholecalciferol D3, Olive oil - Asthma, Respiratory Tract Infections | Phase 3 | Recruiting | Professor Klaus Bønnelykke | 2000 | 2024-12-20 | 2025-09-30 |
Showing 20 of 32. Sign in to see all of them.
Hypersensitivity (5) · Rhinitis, Allergic (3) · Croup (2) · Eczema (2) · Fractures, Bone (2) · Infections (2) · Mental Disorders (2) · Respiratory Sounds (2) · Respiratory Tract Infections (2) · Bronchial Spasm (1) · Churg-Strauss Syndrome (1) · Disease (1) · Hypereosinophilic Syndrome (1) · Pulmonary Eosinophilia (1)
Bronchial Diseases (32) · Hypersensitivity, Immediate (32) · Immune System Diseases (32) · Lung Diseases (32) · Lung Diseases, Obstructive (32) · Respiratory Hypersensitivity (32) · Respiratory Tract Diseases (32) · Hypersensitivity (27) · Otorhinolaryngologic Diseases (5) · Nose Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Rhinitis (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Dermatitis (2)
Budesonide (4) · Standard of Care (3) · Beclomethasone (2) · Budesonide, Formoterol Fumarate Drug Combination (2) · tezepelumab (2) · Albuterol (1) · Fatty Acids, Omega-3 (1) · Fluticasone (1) · Fluticasone-Salmeterol Drug Combination (1) · Foster Home Care (1) · Magnesium Sulfate (1) · Olive Oil (1) · QMF149 (1) · Saline Solution (1) · benralizumab (1)
GlaxoSmithKline (6) · AstraZeneca (5) · Inmunotek S.L. (3) · Generate Biomedicines (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Professor Klaus Bønnelykke (2) · Chiesi Farmaceutici S.p.A. (1) · Franciscus Gasthuis (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Lunan Better Pharmaceutical Co., LTD. (1) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1) · Shanghai Mabgeek Biotech.Co.Ltd (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1) · Suzanne Schuh (1)
United States (13) · China (11) · Spain (8) · United Kingdom (7) · Argentina (6) · Canada (6) · South Africa (6) · France (5) · Italy (5) · Hungary (4) · Netherlands (4) · Romania (4) · South Korea (4) · Belgium (3) · Brazil (3)
Bo Chawes, PhD (2) · Chen Wang Academician, Principal Investigator (1) · FengMing Luo, Professor (1) · Francisco Moreno, MD (1) · JingLi L Li, Medical Ph.D (1) · KeFang Lai, Professor (1) · Limakatso Lebina, PhD (1) · Min Zhang (1)
PMID 39740942, PMID 40382637, PMID 41253413, PMID 41791845, PMID 41967704
2018 (1), 2025 (1)